{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:51:21Z","timestamp":1761519081634,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/s1470-2045(13)70583-7","type":"journal-article","created":{"date-parts":[[2013,12,10]],"date-time":"2013-12-10T21:06:09Z","timestamp":1386709569000},"page":"15-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Which bisphosphonate to treat bone metastases?"],"prefix":"10.1016","volume":"15","author":[{"given":"Luis","family":"Costa","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(13)70583-7_bib1","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(13)70583-7_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1016\/S1470-2045(13)70583-7_bib3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(13)70583-7_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474","article-title":"Bisphosphonates for breast cancer","volume":"1","author":"Pavlakis","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/S1470-2045(13)70583-7_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1634\/theoncologist.2007-0245","article-title":"Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases","volume":"15","author":"Aapro","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/S1470-2045(13)70583-7_bib6","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial","author":"Barrett-Lee","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(13)70583-7_bib7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/S1470-2045(13)70583-7_bib8","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(13)70583-7_bib9","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204513705837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204513705837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:08:37Z","timestamp":1761458917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204513705837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1470204513705837"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(13)70583-7","relation":{},"ISSN":["1470-2045"],"issn-type":[{"type":"print","value":"1470-2045"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which bisphosphonate to treat bone metastases?","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(13)70583-7","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(13)70539-4","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}